万孚生物(300482) - 2025 Q1 - 季度财报

Financial Performance - The company's revenue for Q1 2025 was ¥800,275,782.51, a decrease of 7.06% compared to ¥861,092,255.54 in the same period last year[5] - Net profit attributable to shareholders was ¥189,135,410.14, down 13.37% from ¥218,334,248.48 year-on-year[5] - Basic earnings per share decreased by 20.41% to ¥0.39 from ¥0.49 in the same period last year[5] - Total operating revenue for the current period was ¥800,275,782.51, a decrease of 7.06% from ¥861,092,255.54 in the previous period[18] - Net profit for the current period was ¥190,072,222.04, a decline of 13.75% compared to ¥220,443,620.50 from the previous period[19] - Earnings per share (EPS) for the current period was ¥0.39, down from ¥0.49 in the previous period[20] Cash Flow - The net cash flow from operating activities was -¥148,787,719.58, a significant decline of 231.41% compared to ¥113,224,704.67 in the previous year[5] - Cash inflow from operating activities totaled ¥557,099,837.33, a decrease of 25.06% from ¥743,368,930.59 in the previous period[22] - The net cash flow from operating activities was -$148.79 million, a decrease from $113.22 million in the previous period[23] - The cash outflow for operating activities totaled $705.89 million, compared to $630.14 million previously[23] Assets and Liabilities - Total assets at the end of the reporting period were ¥7,182,545,912.53, reflecting a slight increase of 0.39% from ¥7,154,652,043.13 at the end of the previous year[5] - Current assets totaled CNY 3,824,674,042.04, up from CNY 3,785,861,965.80 at the start of the period[14] - Total current liabilities decreased to CNY 661,546,113.92 from CNY 821,464,141.00, indicating a reduction of approximately 19.5%[15] - The company’s total liabilities decreased to CNY 1,239,504,273.17 from CNY 1,392,436,610.63, indicating a reduction of approximately 11%[15] - Total liabilities amounted to ¥1,342,322,632.33, a decrease from ¥1,504,364,037.54[16] Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 42,296[11] - The company’s equity position remains strong, with significant holdings by major shareholders, including Li Wenmei at 20.32% and Wang Jihua at 10.30%[13] - Total equity attributable to shareholders of the parent company increased to ¥5,743,386,505.55 from ¥5,554,388,042.84[16] Changes in Financial Metrics - The weighted average return on equity was 3.35%, down from 4.50% in the previous year[5] - The company reported a significant increase in accounts receivable by 89.06%, reaching ¥27,575,749.01 due to increased sales revenue settled by notes[9] - The company experienced a 62.99% decrease in cash and cash equivalents, totaling ¥306,674,463.35, primarily due to investments in financial products[9] - The company recorded a 1217.59% increase in fair value gains, amounting to ¥11,431,121.13, attributed to the fair value changes of trading financial assets[9] Inventory and Other Assets - Inventory decreased to CNY 319,592,386.44 from CNY 359,555,274.55, representing a decline of about 11.1%[14] - The company’s non-current assets totaled CNY 3,357,871,870.49, down from CNY 3,368,790,077.33[15] Accounting and Audit - The company did not undergo an audit for the first quarter report[24] - The new accounting standards will be implemented starting in 2025, affecting the financial statements[24]